nodes	percent_of_prediction	percent_of_DWPC	metapath
Pamidronate—Zoledronate—CA2—esophageal cancer	0.0177	0.521	CrCbGaD
Pamidronate—Serum creatinine increased—Capecitabine—esophageal cancer	0.00903	0.00948	CcSEcCtD
Pamidronate—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00874	0.00918	CcSEcCtD
Pamidronate—Nephropathy—Methotrexate—esophageal cancer	0.00869	0.00912	CcSEcCtD
Pamidronate—Hypothyroidism—Capecitabine—esophageal cancer	0.00865	0.00909	CcSEcCtD
Pamidronate—Risedronate—PTGS2—esophageal cancer	0.00863	0.253	CrCbGaD
Pamidronate—Interstitial pneumonia—Methotrexate—esophageal cancer	0.00856	0.00898	CcSEcCtD
Pamidronate—Hypercalcaemia—Capecitabine—esophageal cancer	0.008	0.00839	CcSEcCtD
Pamidronate—Pain—Carboplatin—esophageal cancer	0.00784	0.00823	CcSEcCtD
Pamidronate—Azotaemia—Methotrexate—esophageal cancer	0.00776	0.00815	CcSEcCtD
Pamidronate—Clodronate—PTGS2—esophageal cancer	0.0077	0.226	CrCbGaD
Pamidronate—Hyperkalaemia—Cisplatin—esophageal cancer	0.0074	0.00777	CcSEcCtD
Pamidronate—Herpes zoster—Capecitabine—esophageal cancer	0.00738	0.00775	CcSEcCtD
Pamidronate—Pleural effusion—Capecitabine—esophageal cancer	0.00725	0.00762	CcSEcCtD
Pamidronate—Body temperature increased—Carboplatin—esophageal cancer	0.00725	0.00761	CcSEcCtD
Pamidronate—Coagulopathy—Capecitabine—esophageal cancer	0.00714	0.00749	CcSEcCtD
Pamidronate—Rhinorrhoea—Capecitabine—esophageal cancer	0.00686	0.0072	CcSEcCtD
Pamidronate—Rigors—Capecitabine—esophageal cancer	0.0068	0.00714	CcSEcCtD
Pamidronate—Phlebitis—Cisplatin—esophageal cancer	0.00635	0.00667	CcSEcCtD
Pamidronate—Hypocalcaemia—Capecitabine—esophageal cancer	0.00607	0.00637	CcSEcCtD
Pamidronate—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00603	0.00633	CcSEcCtD
Pamidronate—Herpes simplex—Capecitabine—esophageal cancer	0.00603	0.00633	CcSEcCtD
Pamidronate—Renal failure acute—Cisplatin—esophageal cancer	0.00592	0.00622	CcSEcCtD
Pamidronate—Interstitial lung disease—Methotrexate—esophageal cancer	0.00584	0.00613	CcSEcCtD
Pamidronate—Bone pain—Capecitabine—esophageal cancer	0.0058	0.00609	CcSEcCtD
Pamidronate—Inflammation—Capecitabine—esophageal cancer	0.00573	0.00601	CcSEcCtD
Pamidronate—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00565	0.00593	CcSEcCtD
Pamidronate—Herpes zoster—Methotrexate—esophageal cancer	0.00549	0.00577	CcSEcCtD
Pamidronate—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00547	0.00574	CcSEcCtD
Pamidronate—Pleural effusion—Methotrexate—esophageal cancer	0.0054	0.00567	CcSEcCtD
Pamidronate—Influenza like illness—Capecitabine—esophageal cancer	0.00539	0.00566	CcSEcCtD
Pamidronate—Candida infection—Capecitabine—esophageal cancer	0.0053	0.00557	CcSEcCtD
Pamidronate—Blood creatinine increased—Cisplatin—esophageal cancer	0.00512	0.00538	CcSEcCtD
Pamidronate—Hypokalaemia—Cisplatin—esophageal cancer	0.00498	0.00523	CcSEcCtD
Pamidronate—Cramp muscle—Cisplatin—esophageal cancer	0.00493	0.00517	CcSEcCtD
Pamidronate—Nasopharyngitis—Cisplatin—esophageal cancer	0.00489	0.00514	CcSEcCtD
Pamidronate—Phlebitis—Capecitabine—esophageal cancer	0.00468	0.00491	CcSEcCtD
Pamidronate—Thrombophlebitis—Capecitabine—esophageal cancer	0.00466	0.00489	CcSEcCtD
Pamidronate—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00461	0.00484	CcSEcCtD
Pamidronate—Sweating increased—Cisplatin—esophageal cancer	0.00461	0.00484	CcSEcCtD
Pamidronate—Swelling—Capecitabine—esophageal cancer	0.00457	0.0048	CcSEcCtD
Pamidronate—Herpes simplex—Methotrexate—esophageal cancer	0.00449	0.00471	CcSEcCtD
Pamidronate—Renal failure acute—Capecitabine—esophageal cancer	0.00437	0.00459	CcSEcCtD
Pamidronate—Inflammation—Methotrexate—esophageal cancer	0.00426	0.00448	CcSEcCtD
Pamidronate—Atrial fibrillation—Capecitabine—esophageal cancer	0.00426	0.00447	CcSEcCtD
Pamidronate—Renal failure—Cisplatin—esophageal cancer	0.00414	0.00435	CcSEcCtD
Pamidronate—Cardiac failure—Capecitabine—esophageal cancer	0.00413	0.00434	CcSEcCtD
Pamidronate—Lethargy—Capecitabine—esophageal cancer	0.00411	0.00432	CcSEcCtD
Pamidronate—Stomatitis—Cisplatin—esophageal cancer	0.00411	0.00431	CcSEcCtD
Pamidronate—Conjunctivitis—Cisplatin—esophageal cancer	0.0041	0.0043	CcSEcCtD
Pamidronate—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00403	0.00423	CcSEcCtD
Pamidronate—Osteoarthritis—Capecitabine—esophageal cancer	0.00403	0.00423	CcSEcCtD
Pamidronate—Blood creatinine increased—Capecitabine—esophageal cancer	0.00378	0.00397	CcSEcCtD
Pamidronate—Urinary tract disorder—Cisplatin—esophageal cancer	0.00374	0.00392	CcSEcCtD
Pamidronate—Liver function test abnormal—Capecitabine—esophageal cancer	0.00372	0.00391	CcSEcCtD
Pamidronate—Connective tissue disorder—Cisplatin—esophageal cancer	0.00372	0.0039	CcSEcCtD
Pamidronate—Urethral disorder—Cisplatin—esophageal cancer	0.00371	0.00389	CcSEcCtD
Pamidronate—Pulmonary oedema—Methotrexate—esophageal cancer	0.00368	0.00386	CcSEcCtD
Pamidronate—Hypokalaemia—Capecitabine—esophageal cancer	0.00367	0.00385	CcSEcCtD
Pamidronate—Nasopharyngitis—Capecitabine—esophageal cancer	0.00361	0.00379	CcSEcCtD
Pamidronate—Gastritis—Capecitabine—esophageal cancer	0.00357	0.00375	CcSEcCtD
Pamidronate—Eye disorder—Cisplatin—esophageal cancer	0.00354	0.00371	CcSEcCtD
Pamidronate—Flushing—Cisplatin—esophageal cancer	0.00351	0.00369	CcSEcCtD
Pamidronate—Cardiac disorder—Cisplatin—esophageal cancer	0.00351	0.00369	CcSEcCtD
Pamidronate—Influenza—Capecitabine—esophageal cancer	0.00349	0.00366	CcSEcCtD
Pamidronate—Thrombophlebitis—Methotrexate—esophageal cancer	0.00347	0.00364	CcSEcCtD
Pamidronate—Bronchospasm—Capecitabine—esophageal cancer	0.00343	0.0036	CcSEcCtD
Pamidronate—Immune system disorder—Cisplatin—esophageal cancer	0.00342	0.00359	CcSEcCtD
Pamidronate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00341	0.00358	CcSEcCtD
Pamidronate—Sweating increased—Capecitabine—esophageal cancer	0.00339	0.00356	CcSEcCtD
Pamidronate—Alopecia—Cisplatin—esophageal cancer	0.00334	0.00351	CcSEcCtD
Pamidronate—Erythema—Cisplatin—esophageal cancer	0.00329	0.00346	CcSEcCtD
Pamidronate—Malnutrition—Cisplatin—esophageal cancer	0.00329	0.00346	CcSEcCtD
Pamidronate—Neutropenia—Capecitabine—esophageal cancer	0.00326	0.00342	CcSEcCtD
Pamidronate—Renal failure acute—Methotrexate—esophageal cancer	0.00325	0.00341	CcSEcCtD
Pamidronate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00324	0.0034	CcSEcCtD
Pamidronate—Muscle spasms—Cisplatin—esophageal cancer	0.00317	0.00333	CcSEcCtD
Pamidronate—Pneumonia—Capecitabine—esophageal cancer	0.00313	0.00328	CcSEcCtD
Pamidronate—Infestation NOS—Capecitabine—esophageal cancer	0.00311	0.00326	CcSEcCtD
Pamidronate—Infestation—Capecitabine—esophageal cancer	0.00311	0.00326	CcSEcCtD
Pamidronate—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.0031	0.00326	CcSEcCtD
Pamidronate—Lethargy—Methotrexate—esophageal cancer	0.00306	0.00322	CcSEcCtD
Pamidronate—Ill-defined disorder—Cisplatin—esophageal cancer	0.00306	0.00321	CcSEcCtD
Pamidronate—Renal failure—Capecitabine—esophageal cancer	0.00305	0.00321	CcSEcCtD
Pamidronate—Anaemia—Cisplatin—esophageal cancer	0.00304	0.0032	CcSEcCtD
Pamidronate—Stomatitis—Capecitabine—esophageal cancer	0.00303	0.00318	CcSEcCtD
Pamidronate—Conjunctivitis—Capecitabine—esophageal cancer	0.00302	0.00317	CcSEcCtD
Pamidronate—Urinary tract infection—Capecitabine—esophageal cancer	0.00302	0.00317	CcSEcCtD
Pamidronate—Osteoarthritis—Methotrexate—esophageal cancer	0.003	0.00315	CcSEcCtD
Pamidronate—Malaise—Cisplatin—esophageal cancer	0.00297	0.00312	CcSEcCtD
Pamidronate—Haematuria—Capecitabine—esophageal cancer	0.00296	0.00311	CcSEcCtD
Pamidronate—Leukopenia—Cisplatin—esophageal cancer	0.00295	0.0031	CcSEcCtD
Pamidronate—Agranulocytosis—Capecitabine—esophageal cancer	0.0029	0.00304	CcSEcCtD
Pamidronate—FDPS—bronchus—esophageal cancer	0.00286	0.211	CbGeAlD
Pamidronate—Convulsion—Cisplatin—esophageal cancer	0.00285	0.003	CcSEcCtD
Pamidronate—Myalgia—Cisplatin—esophageal cancer	0.0028	0.00294	CcSEcCtD
Pamidronate—Haemoglobin—Capecitabine—esophageal cancer	0.0028	0.00294	CcSEcCtD
Pamidronate—Rhinitis—Capecitabine—esophageal cancer	0.0028	0.00294	CcSEcCtD
Pamidronate—Anxiety—Cisplatin—esophageal cancer	0.00279	0.00293	CcSEcCtD
Pamidronate—FDPS—smooth muscle tissue—esophageal cancer	0.00279	0.207	CbGeAlD
Pamidronate—Haemorrhage—Capecitabine—esophageal cancer	0.00279	0.00293	CcSEcCtD
Pamidronate—Liver function test abnormal—Methotrexate—esophageal cancer	0.00277	0.00291	CcSEcCtD
Pamidronate—Discomfort—Cisplatin—esophageal cancer	0.00277	0.00291	CcSEcCtD
Pamidronate—Urinary tract disorder—Capecitabine—esophageal cancer	0.00275	0.00289	CcSEcCtD
Pamidronate—Connective tissue disorder—Capecitabine—esophageal cancer	0.00274	0.00288	CcSEcCtD
Pamidronate—Urethral disorder—Capecitabine—esophageal cancer	0.00273	0.00287	CcSEcCtD
Pamidronate—Anaphylactic shock—Cisplatin—esophageal cancer	0.00269	0.00282	CcSEcCtD
Pamidronate—Oedema—Cisplatin—esophageal cancer	0.00269	0.00282	CcSEcCtD
Pamidronate—Infection—Cisplatin—esophageal cancer	0.00267	0.0028	CcSEcCtD
Pamidronate—Nervous system disorder—Cisplatin—esophageal cancer	0.00264	0.00277	CcSEcCtD
Pamidronate—Thrombocytopenia—Cisplatin—esophageal cancer	0.00263	0.00276	CcSEcCtD
Pamidronate—Tachycardia—Cisplatin—esophageal cancer	0.00262	0.00276	CcSEcCtD
Pamidronate—Eye disorder—Capecitabine—esophageal cancer	0.00261	0.00274	CcSEcCtD
Pamidronate—Hyperhidrosis—Cisplatin—esophageal cancer	0.0026	0.00273	CcSEcCtD
Pamidronate—Flushing—Capecitabine—esophageal cancer	0.00259	0.00272	CcSEcCtD
Pamidronate—Cardiac disorder—Capecitabine—esophageal cancer	0.00259	0.00272	CcSEcCtD
Pamidronate—FDPS—trachea—esophageal cancer	0.00256	0.19	CbGeAlD
Pamidronate—Anorexia—Cisplatin—esophageal cancer	0.00256	0.00269	CcSEcCtD
Pamidronate—Angiopathy—Capecitabine—esophageal cancer	0.00253	0.00266	CcSEcCtD
Pamidronate—Immune system disorder—Capecitabine—esophageal cancer	0.00252	0.00265	CcSEcCtD
Pamidronate—Mediastinal disorder—Capecitabine—esophageal cancer	0.00251	0.00264	CcSEcCtD
Pamidronate—Hypotension—Cisplatin—esophageal cancer	0.00251	0.00264	CcSEcCtD
Pamidronate—Chills—Capecitabine—esophageal cancer	0.0025	0.00263	CcSEcCtD
Pamidronate—Alopecia—Capecitabine—esophageal cancer	0.00247	0.00259	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00245	0.00257	CcSEcCtD
Pamidronate—Erythema—Capecitabine—esophageal cancer	0.00243	0.00255	CcSEcCtD
Pamidronate—Malnutrition—Capecitabine—esophageal cancer	0.00243	0.00255	CcSEcCtD
Pamidronate—Neutropenia—Methotrexate—esophageal cancer	0.00243	0.00255	CcSEcCtD
Pamidronate—Paraesthesia—Cisplatin—esophageal cancer	0.00241	0.00253	CcSEcCtD
Pamidronate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00241	0.00253	CcSEcCtD
Pamidronate—Dyspnoea—Cisplatin—esophageal cancer	0.0024	0.00252	CcSEcCtD
Pamidronate—Dysgeusia—Capecitabine—esophageal cancer	0.00238	0.0025	CcSEcCtD
Pamidronate—Back pain—Capecitabine—esophageal cancer	0.00235	0.00247	CcSEcCtD
Pamidronate—Decreased appetite—Cisplatin—esophageal cancer	0.00234	0.00245	CcSEcCtD
Pamidronate—Muscle spasms—Capecitabine—esophageal cancer	0.00233	0.00245	CcSEcCtD
Pamidronate—Pneumonia—Methotrexate—esophageal cancer	0.00233	0.00244	CcSEcCtD
Pamidronate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00232	0.00244	CcSEcCtD
Pamidronate—Infestation NOS—Methotrexate—esophageal cancer	0.00231	0.00243	CcSEcCtD
Pamidronate—Infestation—Methotrexate—esophageal cancer	0.00231	0.00243	CcSEcCtD
Pamidronate—Pain—Cisplatin—esophageal cancer	0.0023	0.00241	CcSEcCtD
Pamidronate—Renal failure—Methotrexate—esophageal cancer	0.00227	0.00239	CcSEcCtD
Pamidronate—Stomatitis—Methotrexate—esophageal cancer	0.00225	0.00237	CcSEcCtD
Pamidronate—Ill-defined disorder—Capecitabine—esophageal cancer	0.00225	0.00237	CcSEcCtD
Pamidronate—Conjunctivitis—Methotrexate—esophageal cancer	0.00225	0.00236	CcSEcCtD
Pamidronate—Anaemia—Capecitabine—esophageal cancer	0.00224	0.00236	CcSEcCtD
Pamidronate—Feeling abnormal—Cisplatin—esophageal cancer	0.00222	0.00233	CcSEcCtD
Pamidronate—FDPS—digestive system—esophageal cancer	0.00221	0.163	CbGeAlD
Pamidronate—Haematuria—Methotrexate—esophageal cancer	0.00221	0.00232	CcSEcCtD
Pamidronate—Malaise—Capecitabine—esophageal cancer	0.00219	0.0023	CcSEcCtD
Pamidronate—Syncope—Capecitabine—esophageal cancer	0.00218	0.00229	CcSEcCtD
Pamidronate—Leukopenia—Capecitabine—esophageal cancer	0.00217	0.00228	CcSEcCtD
Pamidronate—Agranulocytosis—Methotrexate—esophageal cancer	0.00216	0.00227	CcSEcCtD
Pamidronate—Loss of consciousness—Capecitabine—esophageal cancer	0.00213	0.00224	CcSEcCtD
Pamidronate—Body temperature increased—Cisplatin—esophageal cancer	0.00213	0.00223	CcSEcCtD
Pamidronate—Cough—Capecitabine—esophageal cancer	0.00212	0.00222	CcSEcCtD
Pamidronate—Hypertension—Capecitabine—esophageal cancer	0.0021	0.0022	CcSEcCtD
Pamidronate—Haemoglobin—Methotrexate—esophageal cancer	0.00209	0.00219	CcSEcCtD
Pamidronate—Haemorrhage—Methotrexate—esophageal cancer	0.00208	0.00218	CcSEcCtD
Pamidronate—Arthralgia—Capecitabine—esophageal cancer	0.00207	0.00217	CcSEcCtD
Pamidronate—Myalgia—Capecitabine—esophageal cancer	0.00207	0.00217	CcSEcCtD
Pamidronate—Anxiety—Capecitabine—esophageal cancer	0.00206	0.00216	CcSEcCtD
Pamidronate—Urinary tract disorder—Methotrexate—esophageal cancer	0.00205	0.00215	CcSEcCtD
Pamidronate—Discomfort—Capecitabine—esophageal cancer	0.00204	0.00214	CcSEcCtD
Pamidronate—Urethral disorder—Methotrexate—esophageal cancer	0.00204	0.00214	CcSEcCtD
Pamidronate—Confusional state—Capecitabine—esophageal cancer	0.002	0.0021	CcSEcCtD
Pamidronate—Oedema—Capecitabine—esophageal cancer	0.00198	0.00208	CcSEcCtD
Pamidronate—Hypersensitivity—Cisplatin—esophageal cancer	0.00198	0.00208	CcSEcCtD
Pamidronate—Infection—Capecitabine—esophageal cancer	0.00197	0.00207	CcSEcCtD
Pamidronate—Shock—Capecitabine—esophageal cancer	0.00195	0.00205	CcSEcCtD
Pamidronate—Nervous system disorder—Capecitabine—esophageal cancer	0.00194	0.00204	CcSEcCtD
Pamidronate—Eye disorder—Methotrexate—esophageal cancer	0.00194	0.00204	CcSEcCtD
Pamidronate—Thrombocytopenia—Capecitabine—esophageal cancer	0.00194	0.00204	CcSEcCtD
Pamidronate—Tachycardia—Capecitabine—esophageal cancer	0.00193	0.00203	CcSEcCtD
Pamidronate—Asthenia—Cisplatin—esophageal cancer	0.00193	0.00203	CcSEcCtD
Pamidronate—Cardiac disorder—Methotrexate—esophageal cancer	0.00193	0.00202	CcSEcCtD
Pamidronate—Hyperhidrosis—Capecitabine—esophageal cancer	0.00192	0.00201	CcSEcCtD
Pamidronate—Anorexia—Capecitabine—esophageal cancer	0.00189	0.00198	CcSEcCtD
Pamidronate—Angiopathy—Methotrexate—esophageal cancer	0.00188	0.00198	CcSEcCtD
Pamidronate—Immune system disorder—Methotrexate—esophageal cancer	0.00188	0.00197	CcSEcCtD
Pamidronate—Mediastinal disorder—Methotrexate—esophageal cancer	0.00187	0.00197	CcSEcCtD
Pamidronate—Chills—Methotrexate—esophageal cancer	0.00186	0.00196	CcSEcCtD
Pamidronate—Hypotension—Capecitabine—esophageal cancer	0.00185	0.00194	CcSEcCtD
Pamidronate—FDPS—lung—esophageal cancer	0.00184	0.136	CbGeAlD
Pamidronate—Diarrhoea—Cisplatin—esophageal cancer	0.00184	0.00193	CcSEcCtD
Pamidronate—Alopecia—Methotrexate—esophageal cancer	0.00184	0.00193	CcSEcCtD
Pamidronate—Malnutrition—Methotrexate—esophageal cancer	0.00181	0.0019	CcSEcCtD
Pamidronate—Erythema—Methotrexate—esophageal cancer	0.00181	0.0019	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00181	0.0019	CcSEcCtD
Pamidronate—Insomnia—Capecitabine—esophageal cancer	0.00179	0.00188	CcSEcCtD
Pamidronate—Paraesthesia—Capecitabine—esophageal cancer	0.00178	0.00187	CcSEcCtD
Pamidronate—Dysgeusia—Methotrexate—esophageal cancer	0.00177	0.00186	CcSEcCtD
Pamidronate—Dyspnoea—Capecitabine—esophageal cancer	0.00177	0.00186	CcSEcCtD
Pamidronate—Back pain—Methotrexate—esophageal cancer	0.00175	0.00184	CcSEcCtD
Pamidronate—Dyspepsia—Capecitabine—esophageal cancer	0.00174	0.00183	CcSEcCtD
Pamidronate—Decreased appetite—Capecitabine—esophageal cancer	0.00172	0.00181	CcSEcCtD
Pamidronate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00171	0.0018	CcSEcCtD
Pamidronate—Vomiting—Cisplatin—esophageal cancer	0.00171	0.00179	CcSEcCtD
Pamidronate—Fatigue—Capecitabine—esophageal cancer	0.00171	0.00179	CcSEcCtD
Pamidronate—Rash—Cisplatin—esophageal cancer	0.0017	0.00178	CcSEcCtD
Pamidronate—Constipation—Capecitabine—esophageal cancer	0.00169	0.00178	CcSEcCtD
Pamidronate—Pain—Capecitabine—esophageal cancer	0.00169	0.00178	CcSEcCtD
Pamidronate—Dermatitis—Cisplatin—esophageal cancer	0.00169	0.00178	CcSEcCtD
Pamidronate—Ill-defined disorder—Methotrexate—esophageal cancer	0.00168	0.00176	CcSEcCtD
Pamidronate—Anaemia—Methotrexate—esophageal cancer	0.00167	0.00175	CcSEcCtD
Pamidronate—Feeling abnormal—Capecitabine—esophageal cancer	0.00163	0.00171	CcSEcCtD
Pamidronate—Malaise—Methotrexate—esophageal cancer	0.00163	0.00171	CcSEcCtD
Pamidronate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00162	0.0017	CcSEcCtD
Pamidronate—Leukopenia—Methotrexate—esophageal cancer	0.00162	0.0017	CcSEcCtD
Pamidronate—Nausea—Cisplatin—esophageal cancer	0.0016	0.00168	CcSEcCtD
Pamidronate—Cough—Methotrexate—esophageal cancer	0.00158	0.00166	CcSEcCtD
Pamidronate—Abdominal pain—Capecitabine—esophageal cancer	0.00157	0.00164	CcSEcCtD
Pamidronate—Body temperature increased—Capecitabine—esophageal cancer	0.00157	0.00164	CcSEcCtD
Pamidronate—Convulsion—Methotrexate—esophageal cancer	0.00157	0.00164	CcSEcCtD
Pamidronate—Arthralgia—Methotrexate—esophageal cancer	0.00154	0.00162	CcSEcCtD
Pamidronate—Myalgia—Methotrexate—esophageal cancer	0.00154	0.00162	CcSEcCtD
Pamidronate—Discomfort—Methotrexate—esophageal cancer	0.00152	0.0016	CcSEcCtD
Pamidronate—Confusional state—Methotrexate—esophageal cancer	0.00149	0.00156	CcSEcCtD
Pamidronate—Anaphylactic shock—Methotrexate—esophageal cancer	0.00148	0.00155	CcSEcCtD
Pamidronate—Infection—Methotrexate—esophageal cancer	0.00147	0.00154	CcSEcCtD
Pamidronate—Hypersensitivity—Capecitabine—esophageal cancer	0.00146	0.00153	CcSEcCtD
Pamidronate—Nervous system disorder—Methotrexate—esophageal cancer	0.00145	0.00152	CcSEcCtD
Pamidronate—Thrombocytopenia—Methotrexate—esophageal cancer	0.00144	0.00152	CcSEcCtD
Pamidronate—Hyperhidrosis—Methotrexate—esophageal cancer	0.00143	0.0015	CcSEcCtD
Pamidronate—Asthenia—Capecitabine—esophageal cancer	0.00142	0.00149	CcSEcCtD
Pamidronate—Anorexia—Methotrexate—esophageal cancer	0.00141	0.00148	CcSEcCtD
Pamidronate—Pruritus—Capecitabine—esophageal cancer	0.0014	0.00147	CcSEcCtD
Pamidronate—Hypotension—Methotrexate—esophageal cancer	0.00138	0.00145	CcSEcCtD
Pamidronate—Diarrhoea—Capecitabine—esophageal cancer	0.00136	0.00142	CcSEcCtD
Pamidronate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00134	0.00141	CcSEcCtD
Pamidronate—Insomnia—Methotrexate—esophageal cancer	0.00133	0.0014	CcSEcCtD
Pamidronate—Paraesthesia—Methotrexate—esophageal cancer	0.00132	0.00139	CcSEcCtD
Pamidronate—Dyspnoea—Methotrexate—esophageal cancer	0.00132	0.00138	CcSEcCtD
Pamidronate—Somnolence—Methotrexate—esophageal cancer	0.00131	0.00138	CcSEcCtD
Pamidronate—Dizziness—Capecitabine—esophageal cancer	0.00131	0.00138	CcSEcCtD
Pamidronate—Dyspepsia—Methotrexate—esophageal cancer	0.0013	0.00136	CcSEcCtD
Pamidronate—Decreased appetite—Methotrexate—esophageal cancer	0.00128	0.00135	CcSEcCtD
Pamidronate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00127	0.00134	CcSEcCtD
Pamidronate—Fatigue—Methotrexate—esophageal cancer	0.00127	0.00134	CcSEcCtD
Pamidronate—Pain—Methotrexate—esophageal cancer	0.00126	0.00132	CcSEcCtD
Pamidronate—FDPS—lymph node—esophageal cancer	0.00126	0.0932	CbGeAlD
Pamidronate—Vomiting—Capecitabine—esophageal cancer	0.00126	0.00132	CcSEcCtD
Pamidronate—Rash—Capecitabine—esophageal cancer	0.00125	0.00131	CcSEcCtD
Pamidronate—Dermatitis—Capecitabine—esophageal cancer	0.00125	0.00131	CcSEcCtD
Pamidronate—Headache—Capecitabine—esophageal cancer	0.00124	0.0013	CcSEcCtD
Pamidronate—Feeling abnormal—Methotrexate—esophageal cancer	0.00122	0.00128	CcSEcCtD
Pamidronate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00121	0.00127	CcSEcCtD
Pamidronate—Nausea—Capecitabine—esophageal cancer	0.00118	0.00124	CcSEcCtD
Pamidronate—Body temperature increased—Methotrexate—esophageal cancer	0.00117	0.00122	CcSEcCtD
Pamidronate—Abdominal pain—Methotrexate—esophageal cancer	0.00117	0.00122	CcSEcCtD
Pamidronate—Hypersensitivity—Methotrexate—esophageal cancer	0.00109	0.00114	CcSEcCtD
Pamidronate—Asthenia—Methotrexate—esophageal cancer	0.00106	0.00111	CcSEcCtD
Pamidronate—Pruritus—Methotrexate—esophageal cancer	0.00104	0.0011	CcSEcCtD
Pamidronate—Diarrhoea—Methotrexate—esophageal cancer	0.00101	0.00106	CcSEcCtD
Pamidronate—Dizziness—Methotrexate—esophageal cancer	0.000976	0.00102	CcSEcCtD
Pamidronate—Vomiting—Methotrexate—esophageal cancer	0.000938	0.000985	CcSEcCtD
Pamidronate—Rash—Methotrexate—esophageal cancer	0.00093	0.000977	CcSEcCtD
Pamidronate—Dermatitis—Methotrexate—esophageal cancer	0.000929	0.000976	CcSEcCtD
Pamidronate—Headache—Methotrexate—esophageal cancer	0.000924	0.00097	CcSEcCtD
Pamidronate—Nausea—Methotrexate—esophageal cancer	0.000876	0.00092	CcSEcCtD
